SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aventus

Aventus ($AVT.X) is trending on Stocktwits, with community members highlighting its low market cap and Coinbase listing as potential catalysts for a price surge. Some users are pointing to impressive company updates and partnerships as reasons for optimism, while others are focused on technical indicators and breakout potential.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is trending as discussions revolve around lobbying efforts and a potential meeting with President Trump amidst an ongoing DOJ probe, with community members debating the impact of these factors. Some believe a resolution to the probe is near, while others speculate about the potential for increased regulatory challenges. Retail traders remain bullish on the stock's long-term prospects.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending upwards, driven by a mix of potential Q3 delivery beats, optimism around future growth areas like robotics and energy storage, and anticipation of upcoming Fed rate cuts. Community discussions revolve around the stock's momentum, potential short squeezes, and debate over Elon Musk's influence on the company.

Assemble’s AI agent, News3(NS3), was developed with the goal of revolutionizing Web 3.0 journalism. NS3 delivers crypto and global economic trends quickly and clearly, and leverages advanced AI reasoning capabilities to analyze these trends, enabling market participants to make data-driven decisions. In particular, NS3 utilizes OpenAI’s latest reasoning model as its core engine to analyze crypto and economic trends, providing a range of insights including market psychology, past case analysis, future predictions, ripple effects, and investment strategies in 12 languages.

Assemble Protocol

Assemble Protocol ($ASM.X) is trending as traders discuss potential whale manipulation and accumulation, with some speculating about an impending pump. Community members are analyzing price charts and anticipating a breakout, while also debating the coin's utility and potential for significant gains. There's also discussion around a potential listing on a major exchange.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

DIA is trending as community members discuss potential market manipulation and await key economic data releases this week. There's concern about a possible correction, particularly with high margin leverage and an inverted yield curve, but also some bullish sentiment fueled by potential Fed rate cuts. Discussion also revolves around individual stock performance within the Dow, like Microsoft, and the potential impact of political factors.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

Avantis ($AVNT.X) is surging, driven by a recent listing on major exchanges like Binance, sparking significant buying pressure and high trading volume. The community is buzzing with excitement, anticipating further price increases and drawing comparisons to other successful tokens. Many believe this is just the beginning, with some speculating about substantial gains in the near future.

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Atyr Pharma Inc

aTyr Pharma, Inc

The community is buzzing about aTyr Pharma as they anticipate the release of Phase 3 trial data for Efzofitimod, a drug targeting pulmonary sarcoidosis; many expect the data drop sometime next week. Community talking points range from potential FDA approval and buyout scenarios to skepticism fueled by bearish perspectives. Some traders are strategizing around options, with implied volatility high as the community speculates on whether the results will trigger a short squeeze or a significant price drop.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending as the community discusses its potential correlation with Ethereum's price movements and anticipation surrounding possible rate cuts, with some speculating about a significant boost from Tom Lee's future announcements. Community members are weighing the stock's premium and potential arbitrage opportunities, while others are analyzing technical indicators for potential breakouts. The discussion also includes the company's growing Ethereum treasury and its strategic direction as a crypto hedge fund.

GlucoTrack, Inc. designs, develops, and commercializes non-invasive glucose monitoring devices for use by persons suffering from diabetes. The company offers the GlucoTrack model DF-F glucose monitoring device, which utilizes a patented combination of ultrasound, electromagnetic and thermal technologies to obtain glucose measurements in less than one minute via a small sensor that is clipped onto one's earlobe and connected to a small, handheld control and display unit, all without drawing blood or interstitial fluid. It was designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain. The company was founded by Avner Gal and David Malka in September 2001 and is headquartered in Rutherford, NJ.

GlucoTrack Inc

GCTK is trending as traders discuss the company's recent $20 million investment agreement and upcoming presentation at a virtual investor summit, anticipating potential catalysts and news. Community members are weighing the potential for a short squeeze given the low float and upcoming events, while others caution about potential dilution and past reverse splits. The company's glucose monitoring technology and potential competition with larger players like Dexcom and Abbott are also key discussion points.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is trending amid discussions about its AI strategy and potential benefits from its partnership with OpenAI. Community members are analyzing chart patterns, with some anticipating a breakout and others highlighting potential resistance levels. Broader conversations touch on Microsoft's position within the tech sector and its competition with other major players in the AI space.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Cabaletta Bio (CABA) Upgraded to Buy: Here's Why

Cabaletta Bio (CABA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Cabaletta Bio shares hit their highest levels in nearly two months on Thursday following an announcement of crucial regulatory and clinical progress for its leading autoimmune therapy, rese-cel.CABA shares closed up 2.36% at $164.70 on Thursday.The company said it has expanded its RESET-Myositis trial with two new subtypes-specific patient cohorts containing approximately 15 patients each.&nbsp;The expansion followed the U.S. FDA's approval of RMAT designation for rese-cel, which shows its potential treatment for myositis in Americans who have few therapeutic options.The company plans to submit a Biologics License Application (BLA) for rese-cel in 2027 based on a registrational study design that follows FDA guidelines.&nbsp;The RESET clinical development program enrolled 44 patients and administered doses to 23 by May 9.The RESET trials for myositis, systemic autoimmune diseases, SLE/LN, and systemic sclerosis will reveal new clinical data during the EULAR 2025 Congress in June.&nbsp;Cabaletta intends to begin registrational discussions with the FDA regarding SLE and lupus nephritis during Q3 2025, followed by conversations about systemic sclerosis in Q4 2025.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 3,500% surge in 24-hour message volume.Some traders said they reached one of their target prices for CABA and have exited their positions but remain optimistic about a possible upward move tomorrow, keeping an eye out for re-entry opportunities.&nbsp;<stembedurl>https://stocktwits.com/Mr_Stochastic/message/614829609</stembedurl>Another user highlighted that after-hours trading already accounted for a third of the daily volume within the first hour, expressing bullish expectations for the stock to open higher and potentially reach $10 within six months.<stembedurl>https://stocktwits.com/alecsalaur198/message/614824832</stembedurl>The stock has declined 55% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cabaletta Bio Stock Surges To 2-Month High On Autoimmune Therapy Progress; Retail’s Pleased

The company announced the addition of two subtype-specific cohorts to its RESET-Myositis trial and received RMAT designation from the FDA for rese-cel.

Equity

Buy Rating Affirmed for Cabaletta Bio Amid Superior CD19 CAR T Therapy Efficacy in Autoimmune Disease Treatment

Wells Fargo analyst Derek Archila maintained a Buy rating on Cabaletta Bio (CABA Research Report) yesterday and set a price target of $20.00. Der...

Stanley Druckenmiller Bet On Biotech, Financial Services in Q1, Trimmed Nvidia Stake

Bloomberg / Contributor / Getty Images

 Key TakeawaysBillionaire Stanley Druckenmiller added more than three dozen new positions to his portfolio in the first quarter, including Apple, Reddit...

Citigroup Boosts Cabaletta Bio (NASDAQ:CABA) Price Target to $30.00

Cabaletta Bio (NASDAQ:CABA - Free Report) had its price objective lifted by Citigroup from $26.00 to $30.00 in a report published on Thursday morning, Benzinga reports. Citigroup currently has a buy...

Cabaletta Bio (NASDAQ:CABA) PT Raised to $30.00

Cabaletta Bio (NASDAQ:CABA - Get Free Report) had its target price raised by stock analysts at Citigroup from $26.00 to $30.00 in a research note issued to investors on Thursday, Benzinga reports...

Cabaletta Bio price target raised by $4 at Citi, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Cabaletta Bio (CABA, $16.83) Aroon Indicator entered a Downtrend on April 01, 2024.

For the last three days, A.I.dvisor has detected that CABA's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Cabaletta Bio (CABA, $17.04) Aroon Indicator entered a Downtrend on March 28, 2024.

Cabaletta Bio (CABA, $17.14) Aroon Indicator entered a Downtrend on March 27, 2024.

Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA.

CABA
Cabaletta Bio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CABA News

CABA Cabaletta Bio Inc